Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$8.00
-1.6%
$9.98
$6.00
$214.50
$5.42M1.1879,883 shs35,708 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.93
+2.7%
$1.96
$1.35
$53.17
$23.54M0.0780,906 shs58,222 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.16
-1.4%
$3.13
$1.30
$10.00
$20.68MN/A106,527 shs79,261 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%+1.65%+8.25%-74.36%-91.67%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.78%-7.16%+1.19%-45.14%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%+15.57%+2.66%+15.57%-96.12%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
0.00%-6.90%-39.15%+3.85%+980.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$8.00
-1.6%
$9.98
$6.00
$214.50
$5.42M1.1879,883 shs35,708 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.93
+2.7%
$1.96
$1.35
$53.17
$23.54M0.0780,906 shs58,222 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.16
-1.4%
$3.13
$1.30
$10.00
$20.68MN/A106,527 shs79,261 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%+1.65%+8.25%-74.36%-91.67%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.78%-7.16%+1.19%-45.14%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%+15.57%+2.66%+15.57%-96.12%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
0.00%-6.90%-39.15%+3.85%+980.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$320.003,900.00% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17530.40% Upside
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
3.50
Strong Buy$10.00362.96% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($22.02) per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/A$0.47 per shareN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$34.83M0.59$0.26 per share8.23($1.91) per share-1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$83.18N/AN/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.30N/AN/AN/AN/A-2,709.70%-61.16%11/6/2025 (Estimated)
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.12M$0.385.683.66N/A10.02%-18.56%20.28%N/A

Latest BCTX, SNYR, QTTB, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$0.08$0.17+$0.09$0.17$10.80 million$6.74 million
8/6/2025Q2 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.14-$0.78+$0.36-$0.78N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
5.06
5.06
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A
2.74
2.41

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
5.73%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
56.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
8678,000639,000No Data
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
409.44 million4.10 millionN/A

Recent News About These Companies

Financial Review: Synergy CHC (SNYR) and Its Competitors
Critical Survey: Synergy CHC (SNYR) and Its Competitors
Head-To-Head Analysis: Synergy CHC (SNYR) vs. Its Rivals
Analyzing Synergy CHC (SNYR) and Its Competitors
Synergy CHC (SNYR) vs. The Competition Head to Head Analysis
Synergy CHC (SNYR) vs. The Competition Financial Survey
Synergy CHC Completes $4.375M Public Offering
Synergy CHC's (NASDAQ:SNYR) Earnings Quality Is Low

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$8.00 -0.13 (-1.60%)
Closing price 09/12/2025 03:57 PM Eastern
Extended Trading
$7.99 -0.01 (-0.12%)
As of 09/12/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.55 -0.04 (-1.11%)
As of 09/12/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.93 +0.05 (+2.66%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.90 -0.03 (-1.50%)
As of 09/12/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Synergy CHC stock logo

Synergy CHC NASDAQ:SNYR

$2.16 -0.03 (-1.37%)
As of 09/12/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.